Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
NEW ENGLAND JOURNAL OF MEDICINE, cilt.394, sa.11, ss.1139-1140, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Kısa Makale
- Cilt numarası: 394 Sayı: 11
- Basım Tarihi: 2026
- Doi Numarası: 10.1056/nejmc2600540
- Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Abstracts in Social Gerontology, BIOSIS, CINAHL, Educational research abstracts (ERA), EMBASE, Gender Studies Database, MLA - Modern Language Association Database, Public Affairs Index, Nature Index
- Sayfa Sayıları: ss.1139-1140
- Gazi Üniversitesi Adresli: Evet
Özet
To the Editor: The results of the VALIANT trial reported by Fakhouri et al. (Dec. 4 issue)1 provide compelling evidence that proximal C3 inhibition with pegcetacoplan can substantially reduce the degree of proteinuria and stabilize kidney function in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis (MPGN). These results represent a major therapeutic advance for patients with disorders historically associated with poor renal prognosis and limited treatment options.2-5 Beyond its therapeutic implications, the trial reinforces the indispensable role of kidney biopsy in establishing a definitive diagnosis. In contemporary pediatric practice, genetic testing is increasingly being performed before biopsy; however, . . .